Welcome to our dedicated page for CYTR news (Ticker: CYTR), a resource for investors and traders seeking the latest updates and insights on CYTR stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CYTR's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CYTR's position in the market.
CytRx Corporation (OTCQB: CYTR) updates on the FDA's review of Orphazyme A/S's NDA for arimoclomol, aimed at treating Niemann-Pick Disease Type C (NPC). The FDA extended the review period by three months, setting a new PDUFA target action date of June 17, 2021. Despite the extension, the NDA holds Priority Review status, which suggests potential for significant therapeutic advancement. Orphazyme has received several designations for arimoclomol and is committed to the drug's approval and subsequent commercialization in both the U.S. and Europe.
CytRx Corporation (OTCQB: CYTR) congratulated ImmunityBio and NantKwest on their proposed merger, which aims to form a leading company in immunotherapy and cell therapy. CytRx previously out-licensed aldoxorubicin to ImmunityBio in 2017, with potential milestone payments of up to $343 million. The merger is expected to enhance clinical programs, especially the Phase 2 study involving aldoxorubicin for pancreatic cancer. The combined firm will have a vast pipeline of 13 clinical trials across multiple cancer types, potentially transforming treatment options.
FAQ
What is the market cap of CYTR (CYTR)?
